• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cancers (Basel) . Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)

tetano

Editor, Senior Moderator
Cancers (Basel)


. 2022 Apr 27;14(9):2191.
doi: 10.3390/cancers14092191.
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)


Markus Joerger[SUP] 1 [/SUP], Yannis Metaxas[SUP] 2 [/SUP], Khalil Zaman[SUP] 3 [/SUP], Olivier Michielin[SUP] 4 [/SUP], Nicolas Mach[SUP] 5 [/SUP], Adrienne Bettini[SUP] 6 [/SUP], Andreas M Schmitt[SUP] 7 [/SUP], Nathan Cantoni[SUP] 8 [/SUP], Clemens B Caspar[SUP] 9 [/SUP], Sonja Stettler[SUP] 10 [/SUP], Roma Malval[SUP] 11 [/SUP], Miklos Pless[SUP] 12 [/SUP], Christian Britschgi[SUP] 13 [/SUP], Christoph Renner[SUP] 14 [/SUP], Dieter Koeberle[SUP] 15 [/SUP], Jessica D Schulz[SUP] 16 [/SUP], Christoph Kopp[SUP] 16 [/SUP], Stefanie Hayoz[SUP] 16 [/SUP], Anastasios Stathis[SUP] 17 [/SUP], Roger von Moos[SUP] 18 [/SUP], Swiss Group for Clinical Cancer Research (SAKK)



Affiliations
Free article

Abstract

Purpose: These are the final results of a national registry on cancer patients with COVID-19 in Switzerland.
Methods: We collected data on symptomatic COVID-19-infected cancer patients from 23 Swiss sites over a one-year period starting on 1 March 2020. The main objective was to assess the outcome (i.e., mortality, rate of hospitalization, ICU admission) of COVID-19 infection in cancer patients; the main secondary objective was to define prognostic factors.
Results: From 455 patients included, 205 patients (45%) had non-curative disease, 241 patients (53%) were hospitalized for COVID-19, 213 (47%) required oxygen, 43 (9%) invasive ventilation and 62 (14%) were admitted to the ICU. Death from COVID-19 infection occurred in 98 patients, resulting in a mortality rate of 21.5%. Age ≥65 years versus <65 years (OR 3.14, p = 0.003), non-curative versus curative disease (OR 2.42, p = 0.012), ICU admission (OR 4.45, p < 0.001) and oxygen requirement (OR 20.28, p < 0.001) were independently associated with increased mortality.
Conclusions: We confirmed high COVID-19 severity and mortality in real-world cancer patients during the first and second wave of the pandemic in a country with a decentralized, high-quality, universal-access health care system. COVID-19-associated mortality was particularly high for those of older age in a non-curative disease setting, requiring oxygen or ICU care.

Keywords: COVID-19; cancer; cancer treatment; coronavirus; pandemic.
 
Back
Top Bottom